Headache in 2021: clinical, biological, and genetic advances

In the past decade, the strenuous efforts of the scientific community have substantially advanced our understanding of primary headaches. This research has promoted the development of novel disease-specific treatments, such as monoclonal antibodies and small molecules targeting the calcitonin gene-related peptide (CGRP) pathway, and agonists of the 5-HT1F receptor. However, despite these major advances, primary headaches still constitute a challenge for clinicians and a major burden for patients and society.